NSETrading Window4h ago · 25 Sept 2026, 01:42 pm

Trading Window

Mankind Pharma Limited · MANKIND

✦ AI Summary

Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern5/10
Regulatory Risk5/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

MANKIND1_25092026134212_Intimation_Trading_window_closure__2026-27_Q2sd.pdf

pdf

Download →
View document text
September 25, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Intimation of Closure of Trading Window Ref.: Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company’s ‘Code of Conduct for Prevention of Insider Trading’ This is to inform you that pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and the Company’s ‘Code of Conduct for Prevention of Insider Trading’, the trading window for dealing in securities of the Company by the designated persons and/or their immediate relatives and/or persons with whom such designated person shares a material financial relationship, will be closed with effect from October 01, 2026 till 48 hours after the declaration of unaudited standalone and consolidated financial results of the Company for the quarter and half year ending on September 30, 2026. The date of Board Meeting for declaration of the unaudited standalone and consolidated financial results of the Company for the quarter and half year ending on September 30, 2026 will be intimated in due course. You are requested to kindly take the same on records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer